Glutamine supplement tested for IBS relief in new study
NCT ID NCT06291038
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking glutamine, a natural amino acid, can reduce symptoms in people with diarrhea-predominant irritable bowel syndrome (IBS-D) who also have increased intestinal permeability (leaky gut). About 60 adults will receive either glutamine or a placebo daily for 8 weeks. The goal is to see if glutamine improves IBS severity scores and gut barrier function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult aged 18 to 75 * Diarrheal irritable bowel syndrome (IBS-D), according to the Rome IV criteria (appendix 2) * Francis score \> 175/500 at inclusion (corresponding to moderate to severe IBS) * Treatments for IBS stable for \>1 month * Affiliation to a social security system * Adult person having read and understood the information letter and signed the consent form * Woman of childbearing age having effective/very effective contraception (Cf. CTFG) (estrogen-progestins or intrauterine device or tubal ligation) for 1 month and a negative urine pregnancy test * Postmenopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit or biologically documented) Exclusion Criteria: * Taking probiotics, anti-inflammatories, corticosteroids or antibiotics systemically (oral or injectable) in the month preceding the study and during the duration of the study treatment, * Known diagnosis of active autoimmune disease (type 1 diabetes, lupus, multiple sclerosis, thyroiditis, ankylosing spondylitis, rheumatoid arthritis or psoriasis) * Known allergy to glutamine, * Contraindication to taking glutamine, protein powder, lactulose or mannitol (including sugar-free chewing gum), * Use of osmotic laxatives and/or taking lactulose and/or protein supplementation (including taking glutamine) in the 4 weeks preceding the start of the study, * Renal insufficiency (GFR\<40mL/min), hepatic insufficiency (PT\<70) or known heart disease, * ATCD of digestive disease (celiac disease, chronic inflammatory bowel disease, abdominal surgery other than appendectomy or cholecystectomy), * Occlusive or subocclusive syndrome, * Digestive perforation or suspicion of perforation, * Abdominal pain syndrome of undetermined cause, * Chronic alcohol consumption (\>14 units/week), * Pregnant or parturient or breastfeeding woman or proven absence of contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/under guardianship or curatorship, * Person participating in research participating in another trial / having participated in another trial within 2 weeks, * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing them from giving informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU CAEN
RECRUITINGCaen, 14033, France
-
Ch Le Havre
RECRUITINGLe Havre, 76290, France
-
Chu Amiens
NOT_YET_RECRUITINGAmiens, 80054, France
-
Chu Rouen
RECRUITINGRouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website teach patients to tame gut pain and skip needless hospital tests?
- Could allergy pills calm irritable bowel syndrome?
- Can cutting certain carbs or gluten calm irritable bowel syndrome?
- Could a nickel allergy explain your Child's stomach pain?
- Ancient wisdom meets AI: could TCM features sharpen colorectal screening?
- Can cutting certain foods calm irritable bowel syndrome?